A few days after the court hearing on an injunction was mysteriously delayed, the settlement of their patent fight over drugs for insulin-like growth factor 1 deficiency is not only taking Insmed Inc.'s Iplex off the market for short stature - decisively clearing the path for Tercica Inc. (along with licensor Genentech Inc.) to market Increlex - but also provides opt-in possibilities that continue their relationship in other indications. (BioWorld Today) Read More
